Resistance against Reverse Transcriptase Inhibitors
نویسندگان
چکیده
منابع مشابه
Resistance against reverse transcriptase inhibitors.
The response to antiretroviral therapy in human immunodeficiency virus (HIV)-infected patients is limited by the emergence of drug resistance. This resistance is a consequence of the high rate of HIV mutation, the high rate of viral replication (especially when potent multidrug therapies are not used or taken reliably), and the selective effect of these drugs, which favors emergence of mutation...
متن کاملResistance mutations against dolutegravir in HIV integrase impair the emergence of resistance against reverse transcriptase inhibitors.
OBJECTIVE Among 1222 antiretroviral-naive patients who received dolutegravir (DTG) as part of first-line therapy, none has developed resistance against this compound after 48-96 weeks of follow-up. Moreover, only four occurrences of virological failure with resistance mutations have been documented in previously drug-experienced patients who received DTG as a first time integrase inhibitor as a...
متن کاملNucleotide Reverse Transcriptase Inhibitors
4 Optimal HIV-1 suppression often is difficult to achieve and maintain with currently available antiretroviral drugs, and viral resistance eventually emerges to many drugs. Chronic antiretroviral therapy is also associated with complications such as body fat redistribution, hypertriglyceridemia and hypercholesterolemia, abnormal glucose metabolism, lactic acidosis, pancreatitis, avascular necro...
متن کاملNucleoside Reverse Transcriptase Inhibitors
Although the incidence of HIV infection among women is increasing, the proportion of women in clinical trials that evaluate interventions for the treatment of HIV infection and its complications has historically been lower than the proportion of women in the HIV/AIDS patient population. Therefore, most knowledge about the efficacy of antiretroviral drugs and the adverse reactions associated wit...
متن کاملHIV Nucleoside Reverse Transcriptase Inhibitors
Currently, 16 antiretroviral drugs are approved for treatment of HIV infection. However, even the best currently available regimens pose challenges with regard to adherence, toxicity, antiviral activity, and resistance. New drug development thus confronts the need for improved convenience and tolerability, reduced toxicity, and improved activity against both wild-type and drug-resistant viruses...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Clinical Infectious Diseases
سال: 2000
ISSN: 1058-4838,1537-6591
DOI: 10.1086/313858